Page 2 - Rocket Pharma News Today

A case is building for the routine use of dexrazoxane to protect the hearts of children with cancer being treated with doxorubicin.

Board expansion brings significant additional gene therapy and corporate development expertise to AnjariumZURICH, Oct. 18, 2022 /PRNewswire/ -- Anjarium Biosciences AG ("Anjarium"), a biotech

Recent developments of interest in cardiovascular medicine

In spite of logistical obstacles from Brexit and the COVID-19 pandemic, Europe’s CGT market is catching up to that of the U.S. 

Global Gene Therapies For Rare Diseases market is expected to reach US$ 11,441.6 Million by 2030, with a CAGR of 21.7% during a forecast period of 2022-2030.

WASHINGTON — In well-treated patients with chronic HF with reduced ejection fraction, omecamtiv mecarbil did not improve measures of exercise capacity over 20 weeks compared with placebo, researchers reported. Exercise is a “cardinal manifestation” of HF but is not improved by current medical therapies, G. Michael Felker, MD, MHS, professor of medicine at Duke Clinical Research

One of Flushing Town Hall's most popular series, Common Ground: Mini-Global Mashups, returns on Sunday, March 13 at 1PM EST with a live presentation of India Meets Egypt. Devoted global music fans can enjoy two solo musicians of different practices and cultural identities performing together in a unique pairing.

Feb 26, 2021 10:10am The Empire State Building will light up again in green, pink, blue and purple to help Rocket Pharma honor Rare Disease Day. (Rocket Pharma) How does an orphan drug pharma company with offices in the Empire State Building amplify rare disease awareness? Ask Rocket Pharmaceuticals. The rare disease specialist convinced its famous landmark landlord to turn its outside lights to green, blue, pink and purple for Rare Disease Day. That was two years ago—and the beginning of its...